Development of a new software tool and analysis method to improve determination of G6PD status by unknown
POSTER PRESENTATION Open Access
Development of a new software tool and analysis
method to improve determination of G6PD status
Michael Kalnoky1, Maria Kahn2*, Sampa Pal2, Nicole LaRue2, Brandon Leader2, Germana Bancone3,
Francois Nosten3, Gonzalo J Domingo2
From Challanges in malaria research: Core science and innovation
Oxford, UK. 22-24 September 2014
8-aminoquinoline drugs are critical to malaria elimina-
tion campaigns due to their unique ability to kill the
dormant liver stage form of Plasmodium vivax. Due to
the potential for hemolytic reactions in G6PD-deficient
patients, safe administration of these drugs requires
assessing a person’s glucose-6-phosphate dehydrogenase
(G6PD) status. Quantitative and qualitative phenotypic
tests that assess overall G6PD activity within a blood
sample are generally able to distinguish between G6PD-
normal and deficient patients, not factoring in red blood
cell (RBC) count and hemoglobin level. A cytofluori-
metric assay (Shah et al. 2012) allows for screening of
G6PD activity within individual RBCs and identifies het-
erozygous females. This method enables the discrimina-
tion of distinct cell populations based on their G6PD
activity, estimating the actual proportion of deficient
RBCs that are likely to hemolyze during drug treatment.
As part of the study, we enhanced the G6PD classifica-
tion method by analyzing data from the cytofluorimetric
assay with a software tool developed at PATH. This
software tool not only mitigates for variations in mea-
surements generated by different flow cytometers, but
also implements a metric for a more quantitative inter-
pretation of cytochemical staining results. PATH devel-
oped the software tool by correlating enzyme activity
(G-6-PDH Kit, Trinity Biotech), genotypic information,
and complete blood cell count data with the distinct
G6PD activity measured by flow cytometry. As an addi-
tional level of validation, the software tool is undergoing
blind testing with several hundred subsequent samples
collected from multiple international sites. PATH plans
to make the software publicly available and hosted
online to aid clinical and research studies in determining
G6PD status.
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